Treatment plan for children with acute lymphoblastic leukemia, observed
Observes new treatment guidelines in children under 18 with acute lymphoblastic leukemia.
Plain-language title generated from the registry record
Registry title: Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
Key facts
- Where
- Dakar, SenegalSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people from birth to 18 years old who have just been diagnosed with acute lymphoblastic leukemia (ALL) and have not had chemotherapy.
- Age
- 0 to 18 years
- Sex
- All sexes
- Disease stage
- First diagnosis of ALL. Cell type FAB L1 or L2 on cell examination (cytology).
- Earlier treatment
- No earlier chemotherapy.
Main reasons for not taking part
- ALL type L3 (Burkitt)
- ALL that was already treated with chemotherapy
- Trisomy 21 (Down syndrome)
Read by machine on 9 November 2026.
Where in Senegal
- Hôpital Aristide Le Dantec, Avenue Pasteur,Dakar, SenegalTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- French Africa Pediatric Oncology Group
- Trial code
- NCT04794296
- Record updated
- 2 March 2026
- Original description
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.Read full original descriptionShow less
Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.
Inclusion: Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2; -.
Exclusion: ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21.